Table 6 Reported adverse effects

From: A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation

 

Placebo (n = 65) * n (%)

MAG-EPA (n = 63) * n (%)

Diarrhea

1 (1.5)

2 (3.2)

Skin rash

2 (3.1)

1 (1.6)

Nausea

1 (1.5)

3 (4.8)

Digestive problems

1 (1.5)

1 (1.6)

Total patients with events

5 (7.7) **

7 (11.1) **

  1. *The sample size is greater than for the main Ki-67 analysis as all patients who underwent radical prostatectomy are included. **1 patient in placebo group and 5 patients in MAG-EPA group stopped study supplementation because of adverse effects.
  2. MAG-EPA monoacylglyceride-conjugated eicosapentaenoic acid.
Back to article page